EGFR and KRAS mutations detected by COLD-PCR.

Figshare2015-12-02 更新2026-04-29 收录

癌症基因组突变检测

分子伴随诊断

数据链接：

https://figshare.com/articles/dataset/_EGFR_and_KRAS_mutations_detected_by_COLD_PCR_/405425 数据链接链接失效反馈

官方服务：

资源简介：

+Refers to known EGFR mutations.*Refers to novel EGFR mutations.∧Refers to not-otherwise specified.

创建时间：

2015-12-02

Mutation Scanning Using MUT-MAP, a High-Throughput, Microfluidic Chip-Based, Multi-Analyte Panel

癌症基因组突变检测

高通量生物标志物

Targeted anticancer therapies rely on the identification of patient subgroups most likely to respond to treatment. Predictive biomarkers play a key role in patient selection, while diagnostic and prog

NIAID Data Ecosystem110

Detection of KRAS, NRAS et BRAF Mutations in Plasma Circulating DNA From Patients With Metastatic Colorectal Cancer

癌症基因组突变检测

活检技术

RAS genotyping is mandatory for the prescription of anti-EGFR (epidermal growth factor receptor) therapies in patients with metastatic colorectal cancer. The standard genotyping is assessed on formali

NIAID Data Ecosystem40

Enhanced Duplex Sequencing methodology for high efficiency error suppression at variable sequencing depths

癌症基因组突变检测

高通量测序错误抑制

Detection of cancer-associated somatic mutations has broad applications for oncology and precision medicine. However, this becomes challenging when DNA from cancer cells is in low abundance such as in

NIAID Data Ecosystem30

Data_Sheet_1_Standardization of Sequencing Coverage Depth in NGS: Recommendation for Detection of Clonal and Subclonal Mutations in Cancer Diagnostics.pdf

癌症基因组突变检测

临床NGS标准化

The insufficient standardization of diagnostic next-generation sequencing (NGS) still limits its implementation in clinical practice, with the correct detection of mutations at low variant allele freq

NIAID Data Ecosystem40

Analytical validation of the Target Selector ctDNA platform featuring single copy detection sensitivity for clinically actionable EGFR , BRAF , and KRAS mutations

液体活检ctDNA突变检测

癌症基因组突变检测

Background Personalized medicine requires accurate molecular profiling for targeted therapy decisions. Insufficient tissue yield or tumor heterogeneity frequently limits the correct tissue biomarker d

NIAID Data Ecosystem40

EGFR and KRAS mutations detected by COLD-PCR.

资源简介：

相关数据集